hsa-miR-122

ncRNA information

ncRNA name

hsa-miR-122

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

SerpinB3

Cancer information

Cancer name

Hepatocellular Carcinoma

Cancer site

Liver

Treatment information

Treatment type

Chemotherapy

Drug

Sorafenib

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Anti-miR-122 transfection increased cell viability in sorafenib-treated Huh-7 cells, while miR-122 overexpression increased sorafenib sensitivity in treated cells, but not in those overexpressing SerpinB3. In conclusion, we demonstrated that miR-122 targets SerpinB3, and its low levels are associated with SerpinB3 positivity and a stem-like phenotype in HCC.

Tissue resource

hepatocellular carcinoma and cirrhotic tissues

hepatocellular carcinoma cell lines HepG2

hepatocellular carcinoma cell lines Hep3B

hepatocellular carcinoma cell lines Huh7

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

St.Orsola-Malpighi University Hospital, University of Padua

American Type Culture Collection

American Type Culture Collection

University of Bari

Country

Italy

Continent

Europe